This video is sponsored by the Duke Clinical Medical Series.
* Case Presentation
* Nonsustained Ventricular Tachycardia after AMI: What Does It Mean?
* Prevalence, Characteristics, and Prognostic Value of NSVT Early After MI
The moderator, Peter Berger, MD, has indicated that he receives research/grant support
from Aventis, Conor, Guilford, Lumen, and Velocimed. Dr. Berger is also a member of an
advisory board for Genentech and Cordis/Johnson & Johnson; he has spoken at scientific
symposia for Aventis, Bristol-Myers Squibb, Genentech, and Guilford. Dr. Berger also
serves as Medical Director and has equity with Lumen, Inc.
The guest, Patrick Hranitzky, MD, has nothing to disclose regarding this CME activity.